Last Updated: August 3, 2026

Mechanism of Action: Oxidation-Reduction Activity


✉ Email this page to a colleague

« Back to Dashboard


Drugs with Mechanism of Action: Oxidation-Reduction Activity

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Provepharm Sas PROVAYBLUE methylene blue SOLUTION;INTRAVENOUS 204630-002 Jul 18, 2019 AP RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Provepharm Sas PROVAYBLUE methylene blue SOLUTION;INTRAVENOUS 204630-001 Apr 8, 2016 AP RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Zydus Lifesciences METHYLENE BLUE methylene blue SOLUTION;INTRAVENOUS 215636-002 Dec 5, 2023 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Zydus Lifesciences METHYLENE BLUE methylene blue SOLUTION;INTRAVENOUS 215636-004 Mar 31, 2026 RX No Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Meitheal METHYLENE BLUE methylene blue SOLUTION;INTRAVENOUS 217380-001 Jan 23, 2025 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Nexus METHYLENE BLUE methylene blue SOLUTION;INTRAVENOUS 217561-001 Nov 21, 2024 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links